NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
ObjectiveCorroborate blood neuron-derived extracellular vesicle (NDEV) alpha-synuclein (αSyn), the CSF αSyn seed amplification assay (αSyn-SAA), and blood microRNA-7-5p (miR-7-5p) as markers for Parkinson's disease (PD) phenoconversion and determine if combining these markers would help select subjects who would be more likely to phenoconvert.MethodsUsing Parkinson Progression Marker Initiative data, time to PD phenoconversion was determined by Hoehn and Yahr scores. Log-rank analysis was used to find cutpoints. Cox regression analysis was used with log[miR-7-5p], log[NDEV αSyn], and the αSyn-SAA. Models included age and sex.ResultsIn a Cox model with baseline log[miR-7-5p], for each unit increase in log[miR-7-5p], there was 1.57 times increased PD phenoconversion (p = 0.003). In a model with baseline log[NDEV αSyn], only baseline age was associated with increased phenoconversion (p InterpretationBlood miR-7-5p, NDEV αSyn, and αSyn-SAA could be used to enrich for prodromal patients likely to develop PD earlier in disease-modifying clinical trials and combining them could further enrich for this population.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.